IMA401 (Phase Ia) clinical trials

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

This study is testing a new medicine, IMA401, for people with advanced cancers that have come back or haven't responded to other treatments. We want to see if it's safe, how well people tolerate it, and if it can help shrink tumours, either alone or with another cancer drug called pembrolizumab.